<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599686</url>
  </required_header>
  <id_info>
    <org_study_id>Changhai Ho</org_study_id>
    <nct_id>NCT04599686</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer</brief_title>
  <official_title>Androgen Deprivation Therapy (ADT) Versus Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer: A Prospective Randomized Control Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the safety and feasibility of SBRT without ADT in&#xD;
      oligometastatic prostate cancer in patients for whom the standard treatment is ADT, and to&#xD;
      further explore how long only radiotherapy for oligometastases can prolong biochemical&#xD;
      progression-free survival (bPFS). In this study, men with oligometastatic prostate cancer&#xD;
      lesions will be randomized (1:1) to ADT versus SBRT. Within 6 weeks of the oligometastases&#xD;
      diagnosis, ADT or SBRT (30-50Gy with 3-5 fractions) will be administered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The oligometastatic disease state is an increasingly recognized phenomenon in prostate&#xD;
      cancer. Ga-68 PSMA PET/CT has high accuracy in the diagnosis metastases from prostate cancer.&#xD;
      In this protocol, pretreatment Ga-68 PSMA PET/ CT shall be performed in all patients.&#xD;
&#xD;
      ADT is considered standard of care treatment for advanced prostate cancer. But hormonal&#xD;
      therapy can have side effects that greatly trouble men and lead to castration-resistant&#xD;
      prostate cancer (CRPC). Any effort to delay the start of hormonal therapy would be an&#xD;
      advantage to the patient. Stereotactic body radiation therapy (SBRT) is highly focused&#xD;
      radiation, given in a very dose intensive fashion and delivered in usually less than one&#xD;
      week. SBRT has been shown to be very effective on bone or lymph nodes metastases. Therefore,&#xD;
      we are studying the safety and feasibility of SBRT on patients with five or fewer prostate&#xD;
      cancer bone or lymph nodes metastases to determine if we can stall the use of hormonal&#xD;
      therapy and/or prevent other site metastases from developing elsewhere in the body.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 11, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year ADT-free survival of the experimental group</measure>
    <time_frame>Assessment ADT-free survival of the experimental group at 1 year</time_frame>
    <description>To assess ADT-free survival of the experimental group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Probability of Radiotherapy-related Toxicity</measure>
    <time_frame>Assessment Toxicity at 1 year</time_frame>
    <description>Radiotherapy-related complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time from inception of the study to castration-resistant prostate cancer (CRPC)</measure>
    <time_frame>Assessment at 1 year</time_frame>
    <description>the time from inception of the study to castration-resistant prostate cancer (CRPC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year Efficacy Biochemical Progression-free Survival (bPFS)</measure>
    <time_frame>1 year</time_frame>
    <description>Biochemical Progression-free Survival (bPFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Local Progression-Free-Survival(LPFS)</measure>
    <time_frame>Assessment at 1 year</time_frame>
    <description>Local Progression-Free-Survival(LPFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Distant Metastasis Free Survival(DMFS)</measure>
    <time_frame>Assessment at 1 year</time_frame>
    <description>Distant Metastasis Free Survival(DMFS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>ADT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluating men with oligometastatic prostate cancer lesions randomized to ADT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADT</intervention_name>
    <description>On the day of enrollment, luteinizing hormone-releasing hormone agonist (LHRHa) was given for ADT.</description>
    <arm_group_label>ADT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT) (3-5 fractions).</description>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  80 years old&#xD;
&#xD;
               -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Prostate cancer treated with curative intent (radical prostatectomy, primary&#xD;
                  radiotherapy, or a combination of both)&#xD;
&#xD;
               -  Ga-68 prostate-specific membrane antigen (PSMA) PET/CT evidence of one to three&#xD;
                  metastases (bone or lymph node) within 6 weeks of enrolment, if the position of&#xD;
                  oligometastases is judged by the doctor to be in the same radiotherapy area, the&#xD;
                  number of metastases can be appropriately increased to 5&#xD;
&#xD;
               -  Without ADT treatment&#xD;
&#xD;
               -  PSA&lt; 50ng/ml&#xD;
&#xD;
               -  ECOG performance status 0-2&#xD;
&#xD;
               -  Written informed consent according to ICH/GCP regulations before registration and&#xD;
                  prior to any trial specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous or ongoing treatment of oligometastases including radiotherapy, ADT,&#xD;
             chemotherapy, focal treatment, etc.&#xD;
&#xD;
          -  Unstable lesions with spinal or long bone metastases&#xD;
&#xD;
          -  A tumor located at less than 3 mm from the urethra or rectum when measured at the MRI&#xD;
&#xD;
               -  4 metastases, or if the metastases are in the same radiotherapy area, â‰¥6&#xD;
                  metastases&#xD;
&#xD;
          -  Histologically confirmed neuroendocrine tumor or small cell carcinoma of the prostate&#xD;
&#xD;
          -  Severe or active co-morbidity likely to impact on the advisability of SBRT like severe&#xD;
             liver or kidney dysfunction, etc.&#xD;
&#xD;
          -  Patients with other malignancies, or acute or other severe infections, with ulcerative&#xD;
             colitis, inflammatory bowel disease, etc.&#xD;
&#xD;
          -  Patients who have participated in other clinical trials for less than three months&#xD;
&#xD;
          -  Unsuitable to participate in this clinical trial judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huojun Zhang, PhD</last_name>
    <phone>021-31162222</phone>
    <email>chyyzhj@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xianzhi Zhao, MD</last_name>
    <phone>021-31162222</phone>
    <email>zhxzh0007@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huojun Zhang, M.D.</last_name>
      <phone>021-31162222</phone>
      <email>chyyzhj@163.com</email>
    </contact>
    <investigator>
      <last_name>Huojun Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 10, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Huo Jun</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>SBRT</keyword>
  <keyword>Oligometastatic Prostate Cancer</keyword>
  <keyword>Feasibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

